<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:31:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4357386" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4357386</identifier>
        <datestamp>2015-03-23</datestamp>
        <setSpec>plospath</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plospath</journal-id>
              <journal-title-group>
                <journal-title>PLoS Pathogens</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1553-7366</issn>
              <issn pub-type="epub">1553-7374</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4357386</article-id>
              <article-id pub-id-type="pmcid">PMC4357386</article-id>
              <article-id pub-id-type="pmc-uid">4357386</article-id>
              <article-id pub-id-type="pmid">25764397</article-id>
              <article-id pub-id-type="pmid">25764397</article-id>
              <article-id pub-id-type="doi">10.1371/journal.ppat.1004667</article-id>
              <article-id pub-id-type="publisher-id">PPATHOGENS-D-14-01521</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Dihydrobiopterin in Adult Falciparum Malaria: Association with Disease Severity, Impaired Microvascular Function and Increased Endothelial Activation</article-title>
                <alt-title alt-title-type="running-head">Decreased Tetrahydrobiopterin and Severity in Adult Falciparum Malaria</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yeo</surname>
                    <given-names>Tsin W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lampah</surname>
                    <given-names>Daniel A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kenangalem</surname>
                    <given-names>Enny</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tjitra</surname>
                    <given-names>Emiliana</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Price</surname>
                    <given-names>Ric N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weinberg</surname>
                    <given-names>J. Brice</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hyland</surname>
                    <given-names>Keith</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Granger</surname>
                    <given-names>Donald L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff009">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anstey</surname>
                    <given-names>Nicholas M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff010">
                    <sup>10</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Menzies School of Health Research-National Institute of Health Research and Development Research Program, and District Ministry of Health, Timika, Papua, Indonesia</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>National Institute of Health Research and Development, Jakarta, Indonesia</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Duke University and VA Medical Centers, Durham, North Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Medical Neurogenetics LLC, Atlanta, Georgia, United States of America</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Division of Infectious Diseases, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah, United States of America</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Division of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Kami</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Albert Einstein College of Medicine, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p>KH is a founder and employee of Medical Neurogenetics LLC. All other authors declare that there are no competing interests. This does not alter our adherence to all PLOS policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="con" id="contrib001">
                  <p>Conceived and designed the experiments: TWY JBW KH DLG NMA. Performed the experiments: TWY DAL EK ET DLG KH. Analyzed the data: TWY RNP NMA. Contributed reagents/materials/analysis tools: KH DLG JBW. Wrote the paper: TWY DAL EK ET RNP JBW KH DLG NMA.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>tsin.yeo@menzies.edu.au</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>3</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2015</year>
              </pub-date>
              <volume>11</volume>
              <issue>3</issue>
              <elocation-id>e1004667</elocation-id>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>6</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>7</day>
                  <month>1</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
                  <license-p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="ppat.1004667.pdf"/>
              <related-article id="d35e304" related-article-type="companion" ext-link-type="doi" xlink:href="10.1371/journal.ppat.1004655">
                <article-title>Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Oxidized Biopterins in Pediatric Falciparum Malaria: Association with Disease Severity</article-title>
              </related-article>
              <abstract>
                <p>Tetrahydrobiopterin (BH<sub>4</sub>) is a co-factor required for catalytic activity of nitric oxide synthase (NOS) and amino acid-monooxygenases, including phenylalanine hydroxylase. BH<sub>4</sub> is unstable: during oxidative stress it is non-enzymatically oxidized to dihydrobiopterin (BH<sub>2</sub>), which inhibits NOS. Depending on BH<sub>4</sub> availability, NOS oscillates between NO synthase and NADPH oxidase: as the BH<sub>4</sub>/BH<sub>2</sub> ratio decreases, NO production falls and is replaced by superoxide. In African children and Asian adults with severe malaria, NO bioavailability decreases and plasma phenylalanine increases, together suggesting possible BH<sub>4</sub> deficiency. The primary three biopterin metabolites (BH<sub>4</sub>, BH<sub>2</sub> and B<sub>0</sub> [biopterin]) and their association with disease severity have not been assessed in falciparum malaria. We measured pterin metabolites in urine of adults with severe falciparum malaria (SM; n=12), moderately-severe malaria (MSM, n=17), severe sepsis (SS; n=5) and healthy subjects (HC; n=20) as controls. In SM, urinary BH<sub>4</sub> was decreased (median 0.16 ¼mol/mmol creatinine) compared to MSM (median 0.27), SS (median 0.54), and HC (median 0.34)]; p&lt;0.001. Conversely, BH<sub>2</sub> was increased in SM (median 0.91 ¼mol/mmol creatinine), compared to MSM (median 0.67), SS (median 0.39), and HC (median 0.52); p&lt;0.001, suggesting increased oxidative stress and insufficient recycling of BH2 back to BH4 in severe malaria. Overall, the median BH<sub>4</sub>/BH<sub>2</sub> ratio was lowest in SM [0.18 (IQR: 0.04-0.32)] compared to MSM (0.45, IQR 0.27-61), SS (1.03; IQR 0.54-2.38) and controls (0.66; IQR 0.43-1.07); p&lt;0.001. In malaria, a lower BH<sub>4</sub>/BH<sub>2</sub> ratio correlated with decreased microvascular reactivity (r=0.41; p=0.03) and increased ICAM-1 (r=-0.52; p=0.005). Decreased BH4 and increased BH<sub>2</sub> in severe malaria (but not in severe sepsis) uncouples NOS, leading to impaired NO bioavailability and potentially increased oxidative stress. Adjunctive therapy to regenerate BH4 may have a role in improving NO bioavailability and microvascular perfusion in severe falciparum malaria.</p>
              </abstract>
              <abstract abstract-type="summary">
                <title>Author Summary</title>
                <p>Vascular nitric oxide (NO) bioavailability is decreased in severe falciparum malaria and associated with microvascular dysfunction and increased endothelial activation. Nitric oxide synthase (NOS) requires tetrahydrobiopterin (BH<sub>4</sub>) as a co-factor to convert L-arginine to NO, but when BH<sub>4</sub> is low, NOS is “uncoupled” and produces superoxide instead of NO. In conditions of increased oxidative stress, BH<sub>4</sub> is converted to dihydrobiopterin (BH<sub>2)</sub> and biopterin (B<sub>0</sub>): the resulting BH<sub>2</sub> competes with remaining BH<sub>4</sub> as a competitive inhibitor of NOS, further decreasing NO production. We measured BH<sub>4</sub> and BH<sub>2</sub> in the urine of adults with severe and uncomplicated falciparum malaria and compared results to those of controls or those with sepsis. There was a significant decrease in urinary BH<sub>4</sub> and increase in BH<sub>2</sub> in severe malaria compared to uncomplicated malaria, sepsis, and controls, suggesting increased oxidative stress and insufficient recycling of BH<sub>2</sub> back to BH<sub>4</sub>. The BH<sub>4</sub>/BH<sub>2</sub> ratio was associated with increased risk of severe disease, endothelial activation and microvascular dysfunction, likely through impaired NOS function. This additional mechanism of decreased NO in severe malaria suggests that trials evaluating use of adjunctive L-arginine to increase NO in severe malaria may require concurrent therapy to regenerate BH<sub>4</sub>.</p>
              </abstract>
              <funding-group>
                <funding-statement>The study was funded by the Australian National Health and Medical Research Council (Grant numbers 605807, 1037304 and ICRG ID 283321 and Fellowships to NMA [1042072] and TWY [605831])), the Wellcome Trust (ICRG GR071614MA and Senior Fellowship to RNP [091625]), United States National Institutes of Health [grants number AI041764 (JBW); AI057565 and AI100784 (DLG)], the US Veterans Affairs Medical Research Service (JBW and DLG) and in-kind support from Medical Neurogenetics LLC. The Timika Malaria Research Facility was supported by AusAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="2"/>
                <page-count count="13"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>Malaria remains the most important parasitic infection in humans, causing an estimated 207 million cases and 627,000 deaths in 2010 [<xref rid="ppat.1004667.ref001" ref-type="bibr">1</xref>,<xref rid="ppat.1004667.ref002" ref-type="bibr">2</xref>]. Mortality from severe <italic>Plasmodium falciparum</italic> malaria has decreased with use of intravenous artesunate, but case fatality rates remain at 8% and 15% for African children and Asian adults [<xref rid="ppat.1004667.ref003" ref-type="bibr">3</xref>,<xref rid="ppat.1004667.ref004" ref-type="bibr">4</xref>]. Improved understanding of the pathogenesis of severe falciparum malaria may allow identification of new targets for adjunctive therapy.</p>
              <p>Decreased nitric oxide (NO) bioavailability is associated with increased disease severity in African children as well as Asian adults and children with falciparum malaria [<xref rid="ppat.1004667.ref005" ref-type="bibr">5</xref>–<xref rid="ppat.1004667.ref007" ref-type="bibr">7</xref>], but the full reasons for this observation are not known. Mechanisms identified to date include low levels of L-arginine [the substrate for NO synthase (NOS)] [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>,<xref rid="ppat.1004667.ref008" ref-type="bibr">8</xref>], impaired mononuclear cell NOS2 expression [<xref rid="ppat.1004667.ref005" ref-type="bibr">5</xref>], inhibition of NOS by ADMA [<xref rid="ppat.1004667.ref009" ref-type="bibr">9</xref>,<xref rid="ppat.1004667.ref010" ref-type="bibr">10</xref>], and quenching of NO by increased plasma cell-free hemoglobin [<xref rid="ppat.1004667.ref011" ref-type="bibr">11</xref>]. In Asian adults with moderately severe falciparum malaria (MSM), L-arginine infusion increased endothelial NO and pulmonary NO bioavailability [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>]. However, a pilot trial of low-dose L-arginine infusion in adult severe falciparum malaria (SM) did not result in improvement in endothelial NO bioavailability or lactate clearance [<xref rid="ppat.1004667.ref012" ref-type="bibr">12</xref>]. While greater L-arginine clearance in severe malaria suggest that higher doses may be more effective [<xref rid="ppat.1004667.ref012" ref-type="bibr">12</xref>], additional mechanisms beyond L-arginine deficiency are likely to be involved.</p>
              <p>Tetrahydrobiopterin (BH<sub>4</sub>) is an obligate co-factor for NO synthesis by NOS [<xref rid="ppat.1004667.ref013" ref-type="bibr">13</xref>,<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>]. BH<sub>4</sub> stabilizes the homodimeric NOS enzyme and participates in L-arginine oxidation and heme-iron reduction for NO production. NOS lacking BH<sub>4</sub> remains catalytically active, transferring electrons from NADPH to dioxygen to produce superoxide [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1004667.ref015" ref-type="bibr">15</xref>]. Conversion of NOS catalysis from NO synthesis to superoxide production under conditions of low or absent BH<sub>4</sub> is termed “uncoupling,” meaning that NADPH consumption and oxygen activation are no longer “coupled” to BH<sub>4</sub>-dependent L-arginine oxygenation [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1004667.ref015" ref-type="bibr">15</xref>]. In an oxidizing environment, NOS uncoupling may be related to the instability of BH<sub>4</sub> because this reduced pterin spontaneously oxidizes to quininoid-BH<sub>2</sub>, which rapidly rearranges to the stable metabolite 7,8-dihydrobiopterin (BH<sub>2</sub>) that is inactive as a cofactor for NO synthesis. BH<sub>2</sub> can be reduced back to BH<sub>4</sub> via a tetrahydrofolate-dependent salvage pathway [<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>]. However if BH<sub>2</sub> levels rise at the expense of BH<sub>4</sub> oxidation, BH<sub>2</sub> competes with BH<sub>4</sub> at the NOS active site leading to NOS uncoupling and superoxide production. In cardiovascular disease, an increased BH<sub>4</sub>/BH<sub>2</sub> ratio (as opposed to the BH<sub>4</sub> concentration alone) has been found to be the best correlate for endothelial cell-dependent NO synthesis [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1004667.ref015" ref-type="bibr">15</xref>].</p>
              <p>BH<sub>4</sub> is also a co-factor for the enzyme phenylalanine hydroxylase that converts phenylalanine to tyrosine in the liver. We have found in both African children with cerebral malaria (CM) and Asian adults with SM that plasma phenylalanine levels are markedly increased [<xref rid="ppat.1004667.ref017" ref-type="bibr">17</xref>]. We hypothesized that in SM the systemic level of BH<sub>4</sub>, relative to the oxidized biopterin species (BH<sub>2</sub> + B<sub>0</sub>), would be decreased. This could explain depression in both phenylalanine hydroxylase activity and NOS functionality in severe malaria. Biopterin oxidation states in plasma and urine (which reflect systemic levels) have not been measured in malaria. Therefore we undertook measurements of urinary BH<sub>4</sub>, BH<sub>2</sub> and B<sub>0</sub> in Indonesian adults with SM and MSM and compared these to levels in healthy controls and a group presenting with severe sepsis. We hypothesized that (a) BH<sub>4</sub> levels and BH<sub>4</sub>/BH<sub>2</sub> ratios would be decreased, and BH<sub>2</sub> increased in proportion to malaria disease severity, and (b) decreased BH<sub>4</sub>/BH<sub>2</sub> ratios would be associated with increased endothelial activation and impaired NO-dependent microvascular reactivity.</p>
            </sec>
            <sec sec-type="results" id="sec002">
              <title>Results</title>
              <sec id="sec003">
                <title>Patients</title>
                <p>The clinical features of these subjects have previously been described [<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>]. We measured urinary pterin metabolites in their various oxidized states [(including biopterin (B<sub>0</sub>), 7, 8 dihydrobiopterin (BH<sub>2</sub>), tetrahydrobiopterin (BH<sub>4</sub>), dihydroneopterin (NH<sub>2</sub>) and neopterin (N<sub>0</sub>)] levels in 12 adults with severe malaria (SM) and 17 with moderately severe malaria (MSM), with 20 healthy adults (HCs) and 5 with severe sepsis (SS) as controls. In SM patients, 5 had single organ dysfunction (4 with cerebral malaria and 1 with acute renal failure), while the remaining 7 had two or more severity criteria. All SM and MSM patients received intravenous artesunate. In SS patients, two had pneumonia and gastroenteritis, and one each had pneumonia, gastroenteritis, and meningitis. There were 4 deaths in the SM group, and none in the MSM and SS patients. The baseline demographic details, clinical features, hematological and biochemical results of the patients are summarized in <xref rid="ppat.1004667.t001" ref-type="table">Table 1</xref>.</p>
                <table-wrap id="ppat.1004667.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.ppat.1004667.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Baseline demographics, clinical and laboratory measurements.</title>
                  </caption>
                  <alternatives>
                    <graphic id="ppat.1004667.t001g" xlink:href="ppat.1004667.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">Healthy Controls</th>
                          <th align="left" rowspan="1" colspan="1">Moderately-severe malaria</th>
                          <th align="left" rowspan="1" colspan="1">Severe Malaria</th>
                          <th align="left" rowspan="1" colspan="1">Severe Sepsis</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Number</td>
                          <td align="left" rowspan="1" colspan="1">20</td>
                          <td align="left" rowspan="1" colspan="1">17</td>
                          <td align="left" rowspan="1" colspan="1">12</td>
                          <td align="left" rowspan="1" colspan="1">5</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age; years, (median, IQR)</td>
                          <td align="left" rowspan="1" colspan="1">29 (21–35)</td>
                          <td align="left" rowspan="1" colspan="1">28 (23–32)</td>
                          <td align="left" rowspan="1" colspan="1">30 (21–37)</td>
                          <td align="left" rowspan="1" colspan="1">25 (24–26)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Males; (number, percentage)</td>
                          <td align="left" rowspan="1" colspan="1">18 (90%)</td>
                          <td align="left" rowspan="1" colspan="1">11 (65%)</td>
                          <td align="left" rowspan="1" colspan="1">9 (75%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (20%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Days of fever before presentation (median, IQR)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                          <td align="left" rowspan="1" colspan="1">2 (2–5)</td>
                          <td align="left" rowspan="1" colspan="1">3 (2–5)</td>
                          <td align="left" rowspan="1" colspan="1">2 (2–5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Systolic Blood Pressure; median (IQR), (mmHg)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">117 (113–126)</td>
                          <td align="left" rowspan="1" colspan="1">106 (100–115)</td>
                          <td align="left" rowspan="1" colspan="1">110 (101–132)</td>
                          <td align="left" rowspan="1" colspan="1">99 (94–101)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diastolic Blood Pressure; median (IQR), (mmHg)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">70 (65–75)</td>
                          <td align="left" rowspan="1" colspan="1">59 (57–64)</td>
                          <td align="left" rowspan="1" colspan="1">64 (61–73)</td>
                          <td align="left" rowspan="1" colspan="1">64 (60–70)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Pulse Rate; median (IQR), (beats/min)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">65 (60–73)</td>
                          <td align="left" rowspan="1" colspan="1">80 (75–88)</td>
                          <td align="left" rowspan="1" colspan="1">90 (80–97)</td>
                          <td align="left" rowspan="1" colspan="1">104 (103–104)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Pulse Oxygen Saturation; mean (range), (% saturation)</td>
                          <td align="left" rowspan="1" colspan="1">99 (96–100)</td>
                          <td align="left" rowspan="1" colspan="1">98 (94–100)</td>
                          <td align="left" rowspan="1" colspan="1">96 (75–100)</td>
                          <td align="left" rowspan="1" colspan="1">99 (96–100)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Temperature; mean (range) (°Celsius)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">36.1 (35–37)</td>
                          <td align="left" rowspan="1" colspan="1">37.1 (35.9–38.9)</td>
                          <td align="left" rowspan="1" colspan="1">37.0 (35.8–39.6)</td>
                          <td align="left" rowspan="1" colspan="1">37.2 (36.7–38.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Leukocyte count; median (IQR), x10<sup>3</sup>/μL<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">6.1 (4.5–6.8)</td>
                          <td align="left" rowspan="1" colspan="1">4.2 (3.7–5.8)</td>
                          <td align="left" rowspan="1" colspan="1">9.8 (7.4–12.0)</td>
                          <td align="left" rowspan="1" colspan="1">18.1 (15.4–22.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hemoglobin; mean (range), (g/dl)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">12.8 (11.2–15.5)</td>
                          <td align="left" rowspan="1" colspan="1">11.5 (9.4–13.3)</td>
                          <td align="left" rowspan="1" colspan="1">12.0 (11.2–13.9)</td>
                          <td align="left" rowspan="1" colspan="1">9.2 (8.8–11.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Platelet; median (IQR), x10<sup>9</sup>/L <xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">153 (110–200)</td>
                          <td align="left" rowspan="1" colspan="1">53 (48–80)</td>
                          <td align="left" rowspan="1" colspan="1">26 (20–98)</td>
                          <td align="left" rowspan="1" colspan="1">96 (76–201)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine; median (IQR), (μmol/L)<xref rid="t001fn001" ref-type="table-fn">*</xref> (normal range: 50 to 110 μmol)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                          <td align="left" rowspan="1" colspan="1">87 (74–106)</td>
                          <td align="left" rowspan="1" colspan="1">182.5 (109–330)</td>
                          <td align="left" rowspan="1" colspan="1">80 (57–230)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Lactate; median ((IQR), (mmol/L)<xref rid="t001fn001" ref-type="table-fn">*</xref> (normal range: 0 to 2mmol)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                          <td align="left" rowspan="1" colspan="1">1.08 (0.9–1.8)</td>
                          <td align="left" rowspan="1" colspan="1">3.11 (1.9–5.1)</td>
                          <td align="left" rowspan="1" colspan="1">1.31 (1.2–1.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Parasite Density; Geometric Mean (95%CI), (parasite/μL)<xref rid="t001fn001" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                          <td align="left" rowspan="1" colspan="1">14512 (8103–25989)</td>
                          <td align="left" rowspan="1" colspan="1">29269 (6453–132740)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Histidine Rich Protein 2; Median (IQR), (log<sub>e</sub> ng/ml)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                          <td align="left" rowspan="1" colspan="1">2.76 (1.94–3.22)</td>
                          <td align="left" rowspan="1" colspan="1">4.26 (3.79–6.86)</td>
                          <td align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p>*p&lt;0.05 (for ANOVA, Kruskal-Wallis or χ<sup>2</sup> test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec004">
                <title>BH<sub>4</sub>, BH<sub>2</sub>, BH<sub>4</sub>/BH<sub>2</sub> ratio, B<sub>0</sub>, NH<sub>2</sub>, N<sub>0</sub> and clinical disease</title>
                <p>BH<sub>4</sub> was decreased in patients with SM (median 0.16 μmol/mmol creatinine; IQR 0.04–0.30) compared to those with MSM (0.27, IQR 0.19–0.41), SS (0.54; IQR 0.48–0.94), and controls (0.34; IQR 0.27–0.46); Kruskal-Wallis p&lt;0.001 (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>, <xref rid="ppat.1004667.g001" ref-type="fig">Fig. 1A</xref>). In contrast, BH<sub>2</sub> was increased in SM (median 0.91 μmol/mmol creatinine; IQR 0.62–1.35) compared to MSM (0.67; IQR 0.52–0.76), SS (0.39; IQR 0.38–0.88) and HCs (0.52: IQR 0.43–0.69); Kruskal-Wallis p&lt;0.001 (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>, <xref rid="ppat.1004667.g001" ref-type="fig">Fig. 1B</xref>). The BH<sub>4</sub>/BH<sub>2</sub> ratio was also decreased in patients with SM (median 0.17; IQR 0.04–0.32) compared to those with MSM (0.45, IQR 0.27–61), SS (1.03; IQR 0.54–2.38) and controls (0.66; IQR 0.43–1.07); Kruskal-Wallis p&lt;0.001 (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>, <xref rid="ppat.1004667.g001" ref-type="fig">Fig. 1C</xref>). Conversely NH<sub>2</sub> and N<sub>0</sub> levels were increased in SM compared to MSM, SS, and HCs (p&lt;0.001) (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>), but there were no significant differences in the total biopterin (BH<sub>4</sub>+BH<sub>2</sub>+B<sub>0</sub>) levels among groups (p = 0.1) (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>, <xref rid="ppat.1004667.g001" ref-type="fig">Fig. 1D</xref>). The ratio of reduced:oxidized neopterin (NH<sub>2</sub>:N<sub>0</sub>) was 4.4 in healthy controls compared to 2.0 in severe malaria (p = 0.002, <xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>). In the 29 patients with malaria, an increased BH<sub>4</sub>/BH<sub>2</sub> ratio was associated with severe disease (p = 0.03), however no significant associations were found for BH<sub>4</sub>, BH<sub>2</sub>, B<sub>0,</sub> total biopterin, NH<sub>2,</sub> N<sub>0</sub> and total neopterin. The risk of death in malaria was not associated with levels of any of the pterin metabolites. There was no association between serum creatinine and urinary BH<sub>4</sub>, BH<sub>2</sub>, N<sub>0</sub> and NH<sub>2</sub> in patients with malaria and in the groups with severe or uncomplicated disease. On controlling for blood creatinine, there was still a significant difference in urinary BH<sub>2</sub> (p = 0.011) and BH<sub>4</sub>/BH<sub>2</sub> (p = 0.04) levels but not BH<sub>4</sub> between the groups.</p>
                <table-wrap id="ppat.1004667.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.ppat.1004667.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Microvascular reactivity, endothelial function and biopterin metabolite values among patient groups.</title>
                  </caption>
                  <alternatives>
                    <graphic id="ppat.1004667.t002g" xlink:href="ppat.1004667.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">Healthy Controls</th>
                          <th align="left" rowspan="1" colspan="1">P value<xref rid="t002fn003" ref-type="table-fn">†</xref>
</th>
                          <th align="left" rowspan="1" colspan="1">Moderately-severe malaria</th>
                          <th align="left" rowspan="1" colspan="1">P value<xref rid="t002fn004" ref-type="table-fn">††</xref>
</th>
                          <th align="left" rowspan="1" colspan="1">Severe Sepsis</th>
                          <th align="left" rowspan="1" colspan="1">P value<xref rid="t002fn005" ref-type="table-fn">†††</xref>
</th>
                          <th align="left" rowspan="1" colspan="1">Severe Malaria</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Number</td>
                          <td align="left" rowspan="1" colspan="1">20</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">17</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">5</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">12</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Recovery StO<sub>2</sub>%second<xref rid="t002fn002" ref-type="table-fn">*</xref> (StO<sub>2recov</sub>) Median (IQR) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">3.5 (3.0–3.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">3.2 (2.75–3.85)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.1</td>
                          <td align="left" rowspan="1" colspan="1">3.1 (2.6–4.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.05</td>
                          <td align="left" rowspan="1" colspan="1">2.8 (1.8–3.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Reactive Hyperemia Peripheral Arterial Tonometry<xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.76 (1.45–2.15)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.06</td>
                          <td align="left" rowspan="1" colspan="1">1.77 (1.6–2.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">1.56 (1.36–1.68)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.2</td>
                          <td align="left" rowspan="1" colspan="1">1.38 (1.27–1.87)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Tetrahydrobiopterin (BH<sub>4</sub>) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.34 (0.27–0.46)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.006</td>
                          <td align="left" rowspan="1" colspan="1">0.27 (0.19–0.41)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.08</td>
                          <td align="left" rowspan="1" colspan="1">0.54 (0.48–0.94)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.008</td>
                          <td align="left" rowspan="1" colspan="1">0.16 (0.04–0.30)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">7, 8 dihydrobiopterin (BH<sub>2</sub>) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.52 (0.43–0.69)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                          <td align="left" rowspan="1" colspan="1">0.67 (0.52–0.76)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">0.39 (0.38–0.88)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.05</td>
                          <td align="left" rowspan="1" colspan="1">0.91 (0.62–1.35)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">B<sub>0</sub> Biopterin<xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.01 (0–0.02)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                          <td align="left" rowspan="1" colspan="1">0.02 (0.01–0.03)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.08</td>
                          <td align="left" rowspan="1" colspan="1">0.03 (0.02–0.07)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.08</td>
                          <td align="left" rowspan="1" colspan="1">0.06 (0.01–0.19)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Urine Total Biopterins (BH<sub>4</sub> + BH<sub>2</sub> + B<sub>0</sub>)</td>
                          <td align="left" rowspan="1" colspan="1">0.94 (0.75–1.18)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.09</td>
                          <td align="left" rowspan="1" colspan="1">0.94 (0.76–1.17)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.2</td>
                          <td align="left" rowspan="1" colspan="1">1.42 (1.35–1.45)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.6</td>
                          <td align="left" rowspan="1" colspan="1">1.14 (0.89–1.84)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BH<sub>4</sub>/BH<sub>2</sub> ratio<xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.67 (0.43–1.08)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.45 (0.27–0.62)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.01</td>
                          <td align="left" rowspan="1" colspan="1">1.03 (0.54–2.38)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                          <td align="left" rowspan="1" colspan="1">0.18 (0.04–0.32)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Dihydroneopterin (NH<sub>2</sub>) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.73 (0.95–3.20)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.001</td>
                          <td align="left" rowspan="1" colspan="1">6.9 (4.90–8.00)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.6</td>
                          <td align="left" rowspan="1" colspan="1">3.02 (2.57–4.80)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.1</td>
                          <td align="left" rowspan="1" colspan="1">6.2 (4.35–9.78)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Neopterin (N<sub>0</sub>) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.45 (0.21–0.72)</td>
                          <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                          <td align="left" rowspan="1" colspan="1">1.86 (1.29–2.84)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">0.85 (0.77–1.47)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                          <td align="left" rowspan="1" colspan="1">4.16 (2.04–5.11)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Total Neopterin (NH<sub>2</sub> + N<sub>0</sub>) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">2.19 (1.16–3.90)</td>
                          <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                          <td align="left" rowspan="1" colspan="1">8.65 (6.40–10.67)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.2</td>
                          <td align="left" rowspan="1" colspan="1">3.87 (3.3–6.24)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">10.78 (6.55–13.60)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">NH2/N<sub>0</sub> Ratio</td>
                          <td align="left" rowspan="1" colspan="1">4.44 (2.52–8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                          <td align="left" rowspan="1" colspan="1">3.57 (2.32–5.38)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">3.23 (2.9–3.58)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.17</td>
                          <td align="left" rowspan="1" colspan="1">1.98 (0.54–5.48)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Phenylalanine (μmol/L) <xref rid="t002fn002" ref-type="table-fn">*</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">54 (51–58)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">101 (84–110)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.09</td>
                          <td align="left" rowspan="1" colspan="1">114 (112–332)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.2</td>
                          <td align="left" rowspan="1" colspan="1">176 (85–250)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Median and IQR unless otherwise stated. All pterin measurements are μmol/mmol creatinine</p>
                    </fn>
                    <fn id="t002fn002">
                      <p>*p&lt;0.05 (for ANOVA, Kruskal-Wallis or χ<sup>2</sup> test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)</p>
                    </fn>
                    <fn id="t002fn003">
                      <p>†Pairwise comparisons between each group and severe malaria using Wilcoxon-Mann-Whitney test: † control vs severe malaria;</p>
                    </fn>
                    <fn id="t002fn004">
                      <p>†† moderately severe malaria vs severe malaria;</p>
                    </fn>
                    <fn id="t002fn005">
                      <p>††† severe sepsis vs severe malaria.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="ppat.1004667.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.ppat.1004667.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Urinary BH4, BH2 concentrations, BH4/BH2 ratios and Biopterin concentration in each group on enrollment (Kruskal-Wallis: p&lt;0.001). Horizontal bars represent pairwise comparisons between disease groups.</title>
                    <p>A. Urine BH4 (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. B. Urine BH2 (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. C. BH4/BH2 ratio in each group on enrollment. Horizontal lines indicate median values for each group. D. Urine Biopterin (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. Horizontal bars represent pairwise comparisons between disease groups.</p>
                  </caption>
                  <graphic xlink:href="ppat.1004667.g001"/>
                </fig>
              </sec>
              <sec id="sec005">
                <title>BH<sub>4</sub>, BH<sub>2</sub>, BH<sub>4</sub>/BH<sub>2</sub> ratio, and biomarkers of severity</title>
                <p>Peripheral parasitemia was correlated with increasing BH<sub>2</sub> (r = 0.46, p = 0.01) and N<sub>0</sub> (r = 0.50, p = 0.006) levels, and parasite biomass (estimated using plasma HRP2) was positively correlated with BH<sub>2</sub> (r = 0.44, p = 0.02), and inversely with the BH<sub>4</sub>/BH<sub>2</sub> ratio (r = -0.41, p = 0.03) in all malaria patients but not after controlling for malarial disease severity. Increasing venous lactate was associated with higher BH<sub>2</sub> levels (r = 0.48, p = 0.008) and a lower BH<sub>4</sub>/BH<sub>2</sub> ratio (r = -0.43, p = 0.01) in all malaria patients but not after controlling for severity of disease.</p>
                <p><bold>BH<sub>4</sub>, BH<sub>2</sub>, BH<sub>4</sub>/BH<sub>2</sub> ratio, microvascular reactivity, and endothelial activation</bold>. Similar to our previous published results [<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>], microvascular reactivity and endothelial function were reduced in SM compared to MSM and HCs (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>). In all malaria patients, higher microvascular reactivity was associated with an increased BH<sub>4</sub>/BH<sub>2</sub> ratio (r = 0.41, p = 0.03) and lower BH<sub>2</sub> levels (r = -0.42, p = 0.024), with no association found for the other biopterin metabolites. The associations with the BH<sub>4</sub>/BH<sub>2</sub> ratio and BH<sub>2</sub> remained significant after controlling for disease severity (partial correlation coefficient = 0.34, p = 0.04 and partial correlation coefficient = -0.38, p = 0.04, respectively). Impaired endothelial function was also associated with increasing BH<sub>2</sub> in all malaria patients (r = -0.42, p = 0.03) and those with severe malaria (r = -0.48, p = 0.04) but not in the MSM group alone. The association between endothelial function and BH<sub>2</sub> remained significant after controlling for disease severity (partial correlation coefficient = -0.37, p = 0.04). Evaluation of markers of endothelial activation showed that ICAM-1 levels were positively associated with BH<sub>2</sub> (r = 0.4, p = 0.02) and inversely associated with BH<sub>4</sub> (r = -0.38, p = 0.04) and the BH<sub>4</sub>/BH<sub>2</sub> ratio (r = -0.52, p = 0.003) in all malaria patients, but only with BH<sub>4</sub>/BH<sub>2</sub> (r = -0.63, p = 0.03) in the SM group. The association between ICAM-1 with BH<sub>4</sub> (partial correlation coefficient = -0.38, p = 0.035) and the BH<sub>4</sub>/BH<sub>2</sub> ratio (partial correlation coefficient = -0.40, p = 0.03) remained significant after adjustment for malaria severity. The level of angiopoietin-2, another marker of malaria severity, was associated with increasing BH<sub>2</sub> (r = 0.44, p = 0.02), but was not significant after adjusting for disease severity.</p>
              </sec>
              <sec id="sec006">
                <title>Plasma phenylalanine, and BH<sub>4</sub>, BH<sub>2</sub>, and the BH<sub>4</sub>/BH<sub>2</sub> ratio</title>
                <p>Plasma phenylalanine levels were significantly increased in SM (median 176 μmol/L, IQR 85–250) compared to MSM (101μmol/L; IQR 84–110), SS (114μmol/L; IQR 112–332), and HCs (54μmol/L; IQR 51–58); Kruskal-Wallis p&lt;0.001 (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>). Among all patients with malaria, plasma phenylalanine levels were inversely related to the BH<sub>4</sub>/BH<sub>2</sub> ratio (r = -0.44, p = 0.04, including after controlling for disease severity [partial correlation coefficient = -0.38, p = 0.04]) and positively related to BH<sub>2</sub> levels (r = 0.39, p = 0.03, including after controlling for disease severity [partial correlation coefficient = 0.48, p = 0.02]), but not BH<sub>4</sub>, B<sub>0</sub>, NH<sub>2,</sub> or N<sub>0</sub>.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec007">
              <title>Discussion</title>
              <p>In adults with falciparum malaria, urinary tetrahydrobiopterin (BH<sub>4</sub>) was decreased and 7, 8-dihydrobiopterin (BH<sub>2</sub>) increased in proportion to disease severity, and a decreased BH<sub>4</sub>/BH<sub>2</sub> ratio was associated with an increased risk of severe disease. The BH<sub>4</sub>/BH<sub>2</sub> ratio is a reliable correlate for endothelial cell-dependent NO synthesis in vascular diseases [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>–<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>]. The finding of an association between decreased BH<sub>4</sub>/BH<sub>2</sub> ratio and increased BH<sub>2</sub> with impaired microvascular reactivity and increased endothelial activation is consistent with a mechanistic role for oxidative stress and vascular NOS dysfunction. The association of increased BH<sub>2</sub> and low BH<sub>4</sub>/BH<sub>2</sub> ratios with increased phenylalanine levels suggests that systemic deficiency of BH<sub>4</sub> causes impaired phenylalanine hydroxylase function as well as NOS dysfunction in malaria.</p>
              <p>We have previously shown decreased systemic NO production in both African children and Indonesian adults, proportional to disease severity [<xref rid="ppat.1004667.ref005" ref-type="bibr">5</xref>,<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>]. In adult falciparum malaria, there is also decreased endothelial and pulmonary NO bioavailability associated with low levels of the NOS substrate L-arginine [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>], increased levels of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) [<xref rid="ppat.1004667.ref010" ref-type="bibr">10</xref>], NO quenching by cell-free hemoglobin [<xref rid="ppat.1004667.ref011" ref-type="bibr">11</xref>] and L-arginine reversible endothelial dysfunction in moderately severe malaria [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>]. The role of the key NOS cofactor, BH<sub>4</sub>, has not hitherto been shown in human malaria. In a recent murine severe malaria model, uncoupling of NOS with increased production of superoxide and impaired microvascular perfusion has been observed, and this was partially reversed by administration of intravenous BH<sub>4</sub> [<xref rid="ppat.1004667.ref019" ref-type="bibr">19</xref>]. Our results suggest that uncoupling of NOS due to decreased BH<sub>4</sub> bioavailability and increased BH<sub>2</sub>, is also a key mechanism of impaired NO bioavailability in human severe falciparum malaria and in pathogenesis of severe disease.</p>
              <p>The physiological role of NOS is oxidation of L-arginine and oxygen reduction to produce NO and citrulline [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1004667.ref015" ref-type="bibr">15</xref>,<xref rid="ppat.1004667.ref020" ref-type="bibr">20</xref>]. BH<sub>4</sub> regulates the coupling of the heme-oxygen intermediate to oxidation of L-arginine in NOS, and deficiency of BH<sub>4</sub> as a co-factor can result in the output changing from NO to superoxide [<xref rid="ppat.1004667.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1004667.ref015" ref-type="bibr">15</xref>,<xref rid="ppat.1004667.ref020" ref-type="bibr">20</xref>]. Increased oxidative stress can convert BH<sub>4</sub> to the oxidized form BH<sub>2</sub>, with the decrease in BH<sub>4</sub> increasing superoxide, resulting in a feed forward cycle with further oxidization of BH<sub>4</sub> to BH<sub>2</sub> [<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>]. Since BH<sub>2</sub> can serve as a competitive inhibitor at the BH<sub>4</sub> binding site in NOS, the BH<sub>4</sub>/BH<sub>2</sub> ratio is likely to determine NOS coupling in malaria and determine the relative proportions of NO and superoxide production, as others have observed <italic>in vitro</italic> [<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>].</p>
              <p>Systemic bioavailability of BH<sub>4</sub> depends on three pathways of pterin metabolism. First is <italic>de novo</italic> synthesis from GTP. A second is regeneration of BH<sub>4</sub> from quinonoid dihydrobiopterin by dihydropteridine reductase (e.g in hepatocytes for phenylalanine hydroxylase activity) and third is the salvage of 7,8 dihydrobiopterin (BH<sub>2</sub>) back to BH<sub>4</sub> via dihydrofolate reductase (important for NOS activity in endothelial cells). We found no diminution of total biopterins excreted, suggesting that mechanisms controlling overall biopterin production are not impaired. Instead the decrease in BH<sub>4</sub> associated with severe malaria appeared to result from its oxidation coupled with inadequate reduction of BH<sub>2</sub> to BH<sub>4</sub>. <italic>In vivo</italic> recycling of BH<sub>2</sub> to BH<sub>4</sub> is the main regulator of the BH<sub>4</sub>:BH<sub>2</sub> ratio, which in turn controls NOS coupling [<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>].</p>
              <p>Our urine collection procedure allowed for capture of pterins, both biopterins and neopterins, in their excreted oxidation states. Our liquid chromatography methods allowed quantification of both dihydroneopterin and neopterin, the reduced and oxidized metabolites found in humans. This was of interest because these measurements provided information, in addition to biopterins redox status, on the partitioning of oxidized and reduced neopterins. We expected high total neopterin values in malaria and in septic patients and indeed this was found (<xref rid="ppat.1004667.t002" ref-type="table">Table 2</xref>). Elevated total neopterin has been reported previously and is the result of interferon-gamma-induced macrophage/monocyte activation with transcriptional induction of <italic>GCH1</italic> mRNA [<xref rid="ppat.1004667.ref021" ref-type="bibr">21</xref>]. Mononuclear phagocytes have extremely low pyruvoyl tetrahydropterin synthase (PTPS) activity. Consequently the product of GTPCH catalysis, 7,8 dihydroneopterin triphosphate, accumulates, is dephosphorylated intracellularly, and diffuses to extracellular fluid and then plasma as NH<sub>2</sub>. Neopterin in healthy controls is excreted primarily as reduced dihydroneopterin (NH<sub>2</sub>:N<sub>0</sub> = 4.4). In patients with severe malaria, despite marked elevation in urinary levels of total neopterins, the portion excreted as NH<sub>2</sub> fell significantly (NH<sub>2</sub>:N<sub>0</sub> = 2.0). Importantly the oxidation of NH<sub>2</sub> to N<sub>0</sub> is non-enzymatic. This suggests a milieu of oxidative stress in SM. It provides additional support for the redox imbalance observed for the biopterins, that is a fall in the ratio of reduced to oxidized metabolites.</p>
              <p>An increase in oxidative stress has been observed in Bangladeshi adults with severe falciparum malaria [<xref rid="ppat.1004667.ref022" ref-type="bibr">22</xref>]. This may explain the increased conversion of BH<sub>4</sub> to BH<sub>2</sub> as seen in this study, with the decreased BH<sub>4</sub>/BH<sub>2</sub> ratio suggesting impaired recycling of BH<sub>2</sub> to BH<sub>4</sub> in severe malaria. Similar to certain cardiovascular diseases [<xref rid="ppat.1004667.ref016" ref-type="bibr">16</xref>], our results suggest it is the BH<sub>4</sub>/BH<sub>2</sub> ratio and not BH<sub>4</sub> or BH<sub>2</sub> alone that reflects NOS coupling in malaria. A decreased BH<sub>4</sub>/BH<sub>2</sub> ratio was associated with an increased risk of severe disease, while decreased BH<sub>4</sub> or BH<sub>2</sub> alone were not associated with risk of severe disease. The association of a decreased BH<sub>4</sub>/BH<sub>2</sub> ratio with impaired microvascular reactivity and endothelial activation, both previously shown to be associated with increased mortality in malaria, suggests that NOS coupling has an important role in determining malaria severity.</p>
              <p>Our results also show that there is impaired microvascular reactivity and increased endothelial activation in severe sepsis, as we have shown previously [<xref rid="ppat.1004667.ref023" ref-type="bibr">23</xref>,<xref rid="ppat.1004667.ref024" ref-type="bibr">24</xref>]. However, it is notable that sepsis patients had <italic>high</italic> BH<sub>4</sub> levels and <italic>high</italic> BH<sub>4</sub>/BH<sub>2</sub> ratios compared to control subjects and malaria patients. The findings of increased BH<sub>4</sub> levels in sepsis are similar to results from a previous study in which plasma biopterin levels were measured with high performance liquid chromatography [<xref rid="ppat.1004667.ref025" ref-type="bibr">25</xref>]. The mechanism(s) of impaired vascular function in these sepsis patients is unclear, but does not appear to be related to impaired BH<sub>4</sub> bioavailability. Furthermore, the high BH<sub>4</sub>/BH<sub>2</sub> ratio in sepsis indicates that the low BH<sub>4</sub>/BH<sub>2</sub> ratio in severe falciparum malaria is not simply a result of a nonspecific pathogen-wide systemic inflammatory response.</p>
              <p>Results from our study also suggest that, in addition to low plasma L-arginine concentrations, increased ADMA and impaired NOS2 expression in severe malaria [<xref rid="ppat.1004667.ref005" ref-type="bibr">5</xref>,<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>,<xref rid="ppat.1004667.ref008" ref-type="bibr">8</xref>,<xref rid="ppat.1004667.ref010" ref-type="bibr">10</xref>], decreased BH<sub>4</sub> and increased BH<sub>2</sub> can also affect NO bioavailability by altering NOS function in malaria. While increased L-arginine clearance in SM was seen in our pilot study of low dose L-arginine in severe malaria [<xref rid="ppat.1004667.ref012" ref-type="bibr">12</xref>], decreased BH<sub>4</sub> and increased BH<sub>2</sub> could result in low NO despite the presence of normal levels of L-arginine. Results of studies with higher doses of L-arginine in severe falciparum malaria (ACTRN 12612000571875) are awaited, but future studies in severe malaria targeting hypoargininemia may need to consider simultaneously increasing both L-arginine and BH<sub>4</sub> to increase NO production by NOS. Use of intravenous BH<sub>4</sub> in patients with endothelial dysfunction associated with hypercholesterolemia and smoking results in acute improvement in endothelial NO production [<xref rid="ppat.1004667.ref026" ref-type="bibr">26</xref>,<xref rid="ppat.1004667.ref027" ref-type="bibr">27</xref>]. However, a randomized controlled trial of oral BH<sub>4</sub> in patients with coronary artery diseases found that BH<sub>4</sub> administration only resulted in increased conversion of BH<sub>4</sub> to BH<sub>2</sub> with no beneficial effects in clinical outcome [<xref rid="ppat.1004667.ref028" ref-type="bibr">28</xref>]. Using anti-oxidants as adjunctive agents in severe malaria could also increase the BH<sub>4</sub>/BH<sub>2</sub> ratio, but a recent trial using intravenous N-acetylcysteine (without BH<sub>4</sub>) in adult severe malaria did not show a benefit in clinical outcomes [<xref rid="ppat.1004667.ref022" ref-type="bibr">22</xref>].</p>
              <p>BH<sub>4</sub> also plays a role as a co-factor for the enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine [<xref rid="ppat.1004667.ref017" ref-type="bibr">17</xref>]. As previously shown [<xref rid="ppat.1004667.ref017" ref-type="bibr">17</xref>], both adults and children with clinical malaria are almost invariably hyperphenylalaninemic at presentation, which originally suggested a deficiency of BH<sub>4</sub> in these patients. Blood levels of phenylalanine are normally tightly regulated between 30–80 μM by the BH<sub>4</sub>-dependent phenylalanine hydroxylase (PAH) in the liver [<xref rid="ppat.1004667.ref017" ref-type="bibr">17</xref>]. The skewed BH<sub>4</sub>/BH<sub>2</sub> ratio and high BH<sub>2</sub> levels in these subjects correlated significantly with hyperphenylalaninemia. Hyperphenylalaninemia in SM is a transient acute abnormality, and it is relatively mild compared to the high levels observed chronically in untreated infants with phenylketonuria, a condition leading to severe brain damage caused by the direct toxicity of phenylalanine [<xref rid="ppat.1004667.ref029" ref-type="bibr">29</xref>]. While it is not clear if the resulting hyperphenylalaninemia in malaria (especially cerebral malaria) is clinically relevant, it provides important supportive evidence for the functional significance of impaired BH<sub>4</sub> bioavailability on BH<sub>4</sub>-dependent enzyme function in severe malaria.</p>
              <p>This study has several limitations. The relatively small number of patients in each group and the small number of deaths in the SM group do not allow us to examine the independent effect of the biopterin metabolites on mortality or adjust for confounding variables. The numbers were however sufficient to demonstrate significant differences between groups. Also, the use of urinary measures of pterin metabolites as a measure of systemic biopterin bioavailability may not fully reflect intracellular concentrations in specific organs, though urinary biopterin quantitation has been shown to reflect systemic biopterin bioavailability [<xref rid="ppat.1004667.ref030" ref-type="bibr">30</xref>–<xref rid="ppat.1004667.ref033" ref-type="bibr">33</xref>]. It is possible that urinary BH<sub>2</sub> and BH<sub>4</sub> quantitation may be affected by renal function, although there was no association between blood creatinine and urinary BH<sub>4</sub>, BH<sub>2</sub>, N<sub>0</sub> and NH<sub>2</sub> in patients with malaria. Furthermore, measurement of the urine BH<sub>4</sub>/BH<sub>2</sub> ratio is independent of creatinine excretion and is therefore not confounded by renal impairment. Importantly, the specialized collection techniques and assays we have used to measure urinary biopterin metabolite levels allow us to exclude artefactual <italic>ex-vivo</italic> oxidation.</p>
              <p>In summary, the BH<sub>4</sub>/BH<sub>2</sub> ratio is decreased in severe falciparum malaria but not in severe sepsis, and it is associated with an increased risk of severe disease, impaired microvascular function and endothelial activation, probably secondary to NOS uncoupling. The elevated levels of BH<sub>2</sub> suggest that increased conversion of BH<sub>4</sub> to BH<sub>2</sub> due to increased oxidative stress and insufficient recycling of BH<sub>2</sub> back to BH<sub>4</sub> are the mechanisms of the low BH<sub>4</sub>/BH<sub>2</sub> ratio in severe malaria. Our findings identify an additional mechanism of impaired NO bioavailability in severe falciparum malaria and pose an additional challenge to NOS-based adjunctive interventions to increase NO bioavailability in severe malaria.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec008">
              <title>Methods</title>
              <p>The study was undertaken at the Mitra Masyarakat Hospital, Timika, Papua, Indonesia, an area with unstable malaria transmission [<xref rid="ppat.1004667.ref034" ref-type="bibr">34</xref>]. Patients ≥18 years of age with severe (SM) or moderately severe (MSM) <italic>Plasmodium falciparum</italic> malaria, or severe sepsis (SS) were enrolled as previously described [<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>]. SM was defined as peripheral parasitemia with ≥1 modified WHO criterion of severity [<xref rid="ppat.1004667.ref035" ref-type="bibr">35</xref>], and MSM was falciparum malaria with fever within the past 48 hours, parasite counts of &gt;1000/μL, requiring admission because of inability to tolerate oral therapy, but without WHO warning signs or severe criteria as previously described. Healthy controls (HC) were non-related hospital visitors without fever in the last 48 hours and no parasitemia. As an additional control for SM, patients with severe sepsis (SS) were also enrolled, defined as clinical evidence of infection, three or more features of the systemic inflammatory response syndrome, and evidence of one or more organ dysfunction, with or without septic shock, according to American College of Chest Physicians criteria, with no parasites by microscopy and a negative rapid diagnostic test for malaria [<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>]. All patients were managed by non-study hospital physicians and treated accordingly with antimalarials and antibiotics using hospital protocols.</p>
              <p>A standardized history and physical examination were documented. Venous blood was collected on enrolment to measure biomarkers of severity, including lactate and plasma histidine rich protein 2 (HRP2), a measure of parasite biomass [<xref rid="ppat.1004667.ref036" ref-type="bibr">36</xref>,<xref rid="ppat.1004667.ref037" ref-type="bibr">37</xref>]. Plasma was obtained within 20 minutes and stored at -70°C for later quantitiation of the NO-dependent measures of endothelial activation, ICAM-1 and angiopoietin-2 by ELISA, as previously described [<xref rid="ppat.1004667.ref037" ref-type="bibr">37</xref>]. Parasite counts were determined by thick and thin film microscopy. Hemoglobin, biochemistry, acid-base parameters, and lactate were measured with a bedside analyzer (i-STAT Corp). Reactive hyperemia peripheral artery tonometry (RH-PAT) was used to measure endothelial NO bioavailability as previously described [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>,<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>]. RH-PAT uses finger probes to measure digital volume changes measured by a pressure transducer before and after application of an ischemic stress using a vascular cuff inflated to 200mmHg for 5 minutes followed by rapid cuff release. The RH-PAT index is a measure of the volume change and is at least 50% dependent on endothelial NO production. Near infrared resonance spectroscopy (NIRS) measurements were performed concurrently to assess microvascular reactivity on enrollment as reported before [<xref rid="ppat.1004667.ref018" ref-type="bibr">18</xref>]. In brief, a clinical spectroscope (InSpectra 650, Hutchinson Technology) was used noninvasively to assess microvascular reactivity by measuring differential absorption of oxy (O<sub>2</sub>Hb) and deoxyhaemoglobin (HHb), which is then displayed as tissue oxygen saturation (ratio of O<sub>2</sub>Hb/O<sub>2</sub>Hb+HHb signals). By inducing an ischemic stress as detailed above, microvascular reactivity is the rate of skeletal muscle reoxygenation, defined as the rate of increase in StO<sub>2</sub> in the first 14 seconds after release of occlusion. According to Beer’s law, this is confined to arterioles, capillaries, and venules of skeletal muscle with minimal interference from skin blood flow and myoglobin.</p>
              <sec id="sec009">
                <title>Measurement of urine pterin compounds</title>
                <p>Measurement of urine pterin concentrations, expressed as biopterins and neopterins in micromoles per millimole urine creatinine are used for diagnosis of gene mutations leading to BH<sub>4</sub> synthesis, recycling and salvage deficiencies and reflect systemic pterin bioavailability [<xref rid="ppat.1004667.ref030" ref-type="bibr">30</xref>–<xref rid="ppat.1004667.ref033" ref-type="bibr">33</xref>]. BH<sub>4</sub> is unstable and spontaneously oxidizes to its inactive metabolites, dihydrobiopterin (BH<sub>2</sub>) and to a lesser extent fully oxidized biopterin (B<sub>0</sub>) [<xref rid="ppat.1004667.ref038" ref-type="bibr">38</xref>,<xref rid="ppat.1004667.ref039" ref-type="bibr">39</xref>]. To prevent ex vivo spontaneous oxidation, urine was collected, via voluntary micturition or immediately after insertion of a Foley catheter, directly into vials containing the antioxidant pterin stabilizers 1,4-dithioerythritol (DTE) and diethylenetriaminepentaacetic acid (DETAPAC) [<xref rid="ppat.1004667.ref038" ref-type="bibr">38</xref>,<xref rid="ppat.1004667.ref039" ref-type="bibr">39</xref>] (as described in <xref rid="ppat.1004667.s001" ref-type="supplementary-material">S1</xref>). Urine was then frozen at -70°C, and shipped in liquid nitrogen to Medical Neurogenetics Laboratories, LLC, Atlanta, GA United States. Concentrations of biopterin, 7,8-dihydrobiopterin, 5,6,7,8-tetrahydrobiopterin, and neopterin were quantified by high performance liquid chromatography using sequential electrochemical and fluorescence detection, as previously described [<xref rid="ppat.1004667.ref038" ref-type="bibr">38</xref>,<xref rid="ppat.1004667.ref039" ref-type="bibr">39</xref>]. Concentrations of pterin metabolites were normalized to creatinine concentrations in millimoles.</p>
              </sec>
              <sec id="sec010">
                <title>Statistical methods</title>
                <p>Statistical analysis was performed using STATA 11 software. The sample size for the patients with severe malaria was calculated from our previous study comparing RH-PAT in adults with severe and uncomplicated malaria with controls [<xref rid="ppat.1004667.ref006" ref-type="bibr">6</xref>]. Using the difference and standard deviations found in RH-PAT index between severe malaria and controls, we estimated that a sample size of 14 in each group would have 80% power to detect a 25% difference between these two groups. Intergroup differences among malaria (MSM and SM) and controls were compared by ANOVA or Kruskal-Wallis test, where appropriate, with Wilcoxon Rank-Sum test used for pairwise comparisons. Pearson’s or Spearman’s correlation coefficients were determined depending on normality of distributions. Partial correlation coefficients were calculated adjusting for malaria disease severity. Logistic regression was used to determine the association between binary outcomes and goodness-of-fit was assessed by the Hosmer-Lemeshow test. A two-sided value of p&lt;0.05 was considered significant.</p>
              </sec>
              <sec id="sec011">
                <title>Ethics statement</title>
                <p>The study was approved by ethics committees of the National Institute of Health Research and Development, Indonesia, and the Menzies School of Health Research, Australia. Written informed consent was obtained from patients or relatives if patients were comatose or too ill to give informed consent. Specific approval for this was obtained from both ethics committees.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material" id="sec012">
              <title>Supporting Information</title>
              <supplementary-material content-type="local-data" id="ppat.1004667.s001">
                <label>S1 Study Protocol</label>
                <caption>
                  <title>The protocol used in the conduct of the study.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="ppat.1004667.s001.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank Retno Gitawati, Indri Rooslamiati, Sri Muliati and Erens Meokbum for their support; Yohanes Kalvein Mira Mangngi for nursing assistance; Ferryanto Chalfein, Prayoga, Kim Piera, Tonia Woodberry and Gabriela Minigo for technical and logistical assistance; Mitra Masyarakat Hospital staff for clinical support; Paulus Sugiarto, Jeanne Rini Poespoprodjo, and Lembaga Pengembangan Masyarakat Amungme Kamoro for support and assistance.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="ppat.1004667.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>NJ</given-names></name>, <name><surname>Pukrittayakamee</surname><given-names>S</given-names></name>, <name><surname>Hien</surname><given-names>TT</given-names></name>, <name><surname>Faiz</surname><given-names>MA</given-names></name>, <name><surname>Mokuolu</surname><given-names>OA</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Malaria</article-title>. <source>Lancet</source>
<volume>383</volume>: <fpage>723</fpage>–<lpage>735</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60024-0</pub-id>
<?supplied-pmid 23953767?><pub-id pub-id-type="pmid">23953767</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref002">
                <label>2</label>
                <mixed-citation publication-type="other">World Health Organization (2013) World Malaria Report 2013.</mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><collab>The SEAQUAMAT Trial Group</collab> (<year>2005</year>) <article-title>Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial</article-title>. <source>Lancet</source>
<volume>366</volume>: <fpage>717</fpage>–<lpage>725</lpage>.
<?supplied-pmid 16125588?><pub-id pub-id-type="pmid">16125588</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Dondorp</surname><given-names>AM</given-names></name>, <name><surname>Fanello</surname><given-names>CI</given-names></name>, <name><surname>Hendriksen</surname><given-names>IC</given-names></name>, <name><surname>Gomes</surname><given-names>E</given-names></name>, <name><surname>Seni</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial</article-title>. <source>Lancet</source>
<volume>376</volume>: <fpage>1647</fpage>–<lpage>1657</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(10)61924-1</pub-id>
<?supplied-pmid 21062666?><pub-id pub-id-type="pmid">21062666</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Anstey</surname><given-names>NM</given-names></name>, <name><surname>Weinberg</surname><given-names>JB</given-names></name>, <name><surname>Hassanali</surname><given-names>MY</given-names></name>, <name><surname>Mwaikambo</surname><given-names>ED</given-names></name>, <name><surname>Manyenga</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression</article-title>. <source>J Exp Med</source>
<volume>184</volume>: <fpage>557</fpage>–<lpage>567</lpage>.
<?supplied-pmid 8760809?><pub-id pub-id-type="pmid">8760809</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Gitawati</surname><given-names>R</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria</article-title>. <source>J Exp Med</source>
<volume>204</volume>: <fpage>2693</fpage>–<lpage>2704</lpage>.
<?supplied-pmid 17954570?><pub-id pub-id-type="pmid">17954570</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Weinberg</surname><given-names>JB</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Decreased Endothelial Nitric Oxide Bioavailability, Impaired Microvascular Function, and Increased Tissue Oxygen Consumption in Children with Falciparum Malaria</article-title>. <source>J Infect Dis</source>.</mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Lopansri</surname><given-names>BK</given-names></name>, <name><surname>Anstey</surname><given-names>NM</given-names></name>, <name><surname>Weinberg</surname><given-names>JB</given-names></name>, <name><surname>Stoddard</surname><given-names>GJ</given-names></name>, <name><surname>Hobbs</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production</article-title>. <source>Lancet</source>
<volume>361</volume>: <fpage>676</fpage>–<lpage>678</lpage>.
<?supplied-pmid 12606182?><pub-id pub-id-type="pmid">12606182</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Weinberg</surname><given-names>JB</given-names></name>, <name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Mukemba</surname><given-names>JP</given-names></name>, <name><surname>Florence</surname><given-names>SM</given-names></name>, <name><surname>Volkheimer</surname><given-names>AD</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Dimethylarginines: Endogenous Inhibitors of Nitric Oxide Synthesis in Children With Falciparum Malaria</article-title>. <source>J Infect Dis</source>.</mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Gitawati</surname><given-names>R</given-names></name>, <name><surname>Darcy</surname><given-names>CJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome</article-title>. <source>PLoS Pathog</source>
<volume>6</volume>: <fpage>e1000868</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1000868</pub-id>
<?supplied-pmid 20421938?><pub-id pub-id-type="pmid">20421938</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Gitawati</surname><given-names>R</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria</article-title>. <source>J Infect Dis</source>
<volume>200</volume>: <fpage>1522</fpage>–<lpage>1529</lpage>. <pub-id pub-id-type="doi">10.1086/644641</pub-id>
<?supplied-pmid 19803726?><pub-id pub-id-type="pmid">19803726</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Rooslamiati</surname><given-names>I</given-names></name>, <name><surname>Gitawati</surname><given-names>R</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics</article-title>. <source>PLoS One</source>
<volume>8</volume>: <fpage>e69587</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069587</pub-id>
<?supplied-pmid 23922746?><pub-id pub-id-type="pmid">23922746</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Griffith</surname><given-names>OW</given-names></name>, <name><surname>Stuehr</surname><given-names>DJ</given-names></name> (<year>1995</year>) <article-title>Nitric oxide synthases: properties and catalytic mechanism</article-title>. <source>Annu Rev Physiol</source>
<volume>57</volume>: <fpage>707</fpage>–<lpage>736</lpage>.
<?supplied-pmid 7539994?><pub-id pub-id-type="pmid">7539994</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Bendall</surname><given-names>JK</given-names></name>, <name><surname>Douglas</surname><given-names>G</given-names></name>, <name><surname>McNeill</surname><given-names>E</given-names></name>, <name><surname>Channon</surname><given-names>KM</given-names></name>, <name><surname>Crabtree</surname><given-names>MJ</given-names></name> (<year>2014</year>) <article-title>Tetrahydrobiopterin in cardiovascular health and disease</article-title>. <source>Antioxid Redox Signal</source>
<volume>20</volume>: <fpage>3040</fpage>–<lpage>3077</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2013.5566</pub-id>
<?supplied-pmid 24294830?><pub-id pub-id-type="pmid">24294830</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Crabtree</surname><given-names>MJ</given-names></name>, <name><surname>Channon</surname><given-names>KM</given-names></name> (<year>2011</year>) <article-title>Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease</article-title>. <source>Nitric Oxide</source>
<volume>25</volume>: <fpage>81</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.niox.2011.04.004</pub-id>
<?supplied-pmid 21550412?><pub-id pub-id-type="pmid">21550412</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Crabtree</surname><given-names>MJ</given-names></name>, <name><surname>Tatham</surname><given-names>AL</given-names></name>, <name><surname>Hale</surname><given-names>AB</given-names></name>, <name><surname>Alp</surname><given-names>NJ</given-names></name>, <name><surname>Channon</surname><given-names>KM</given-names></name> (<year>2009</year>) <article-title>Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways</article-title>. <source>J Biol Chem</source>
<volume>284</volume>: <fpage>28128</fpage>–<lpage>28136</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.041483</pub-id>
<?supplied-pmid 19666465?><pub-id pub-id-type="pmid">19666465</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Lopansri</surname><given-names>BK</given-names></name>, <name><surname>Anstey</surname><given-names>NM</given-names></name>, <name><surname>Stoddard</surname><given-names>GJ</given-names></name>, <name><surname>Mwaikambo</surname><given-names>ED</given-names></name>, <name><surname>Boutlis</surname><given-names>CS</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications</article-title>. <source>Infect Immun</source>
<volume>74</volume>: <fpage>3355</fpage>–<lpage>3359</lpage>.
<?supplied-pmid 16714564?><pub-id pub-id-type="pmid">16714564</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Price</surname><given-names>RN</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria</article-title>. <source>J Infect Dis</source>
<volume>207</volume>: <fpage>528</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis692</pub-id>
<?supplied-pmid 23162136?><pub-id pub-id-type="pmid">23162136</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Ong</surname><given-names>PK</given-names></name>, <name><surname>Melchior</surname><given-names>B</given-names></name>, <name><surname>Martins</surname><given-names>YC</given-names></name>, <name><surname>Hofer</surname><given-names>A</given-names></name>, <name><surname>Orjuela-Sanchez</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Nitric oxide synthase dysfunction contributes to impaired cerebroarteriolar reactivity in experimental cerebral malaria</article-title>. <source>PLoS Pathog</source>
<volume>9</volume>: <fpage>e1003444</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1003444</pub-id>
<?supplied-pmid 23818850?><pub-id pub-id-type="pmid">23818850</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Vasquez-Vivar</surname><given-names>J</given-names></name>, <name><surname>Kalyanaraman</surname><given-names>B</given-names></name>, <name><surname>Martasek</surname><given-names>P</given-names></name>, <name><surname>Hogg</surname><given-names>N</given-names></name>, <name><surname>Masters</surname><given-names>BS</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors</article-title>. <source>Proc Natl Acad Sci</source>
<volume>95</volume>: <fpage>9220</fpage>–<lpage>9225</lpage>.
<?supplied-pmid 9689061?><pub-id pub-id-type="pmid">9689061</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Reibnegger</surname><given-names>G</given-names></name>, <name><surname>Boonpucknavig</surname><given-names>V</given-names></name>, <name><surname>Fuchs</surname><given-names>D</given-names></name>, <name><surname>Hansen</surname><given-names>A</given-names></name>, <name><surname>Schmutzhard</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1984</year>) <article-title>Urinary neopterin is elevated in patients with malaria</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>78</volume>: <fpage>545</fpage>–<lpage>546</lpage>.
<?supplied-pmid 6485060?><pub-id pub-id-type="pmid">6485060</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Charunwatthana</surname><given-names>P</given-names></name>, <name><surname>Abul Faiz</surname><given-names>M</given-names></name>, <name><surname>Ruangveerayut</surname><given-names>R</given-names></name>, <name><surname>Maude</surname><given-names>RJ</given-names></name>, <name><surname>Rahman</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial</article-title>. <source>Crit Care Med</source>
<volume>37</volume>: <fpage>516</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181958dfd</pub-id>
<?supplied-pmid 19114891?><pub-id pub-id-type="pmid">19114891</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>JS</given-names></name>, <name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Thomas</surname><given-names>JH</given-names></name>, <name><surname>McMillan</surname><given-names>M</given-names></name>, <name><surname>Darcy</surname><given-names>CJ</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study</article-title>. <source>Crit Care</source>
<volume>13</volume>: <fpage>R155</fpage>
<pub-id pub-id-type="doi">10.1186/cc8055</pub-id>
<?supplied-pmid 19778457?><pub-id pub-id-type="pmid">19778457</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>JS</given-names></name>, <name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Piera</surname><given-names>KA</given-names></name>, <name><surname>Woodberry</surname><given-names>T</given-names></name>, <name><surname>Celermajer</surname><given-names>DS</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity</article-title>. <source>Crit Care</source>
<volume>14</volume>: <fpage>R89</fpage>
<pub-id pub-id-type="doi">10.1186/cc9020</pub-id>
<?supplied-pmid 20482750?><pub-id pub-id-type="pmid">20482750</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Galley</surname><given-names>HF</given-names></name>, <name><surname>Le Cras</surname><given-names>AE</given-names></name>, <name><surname>Yassen</surname><given-names>K</given-names></name>, <name><surname>Grant</surname><given-names>IS</given-names></name>, <name><surname>Webster</surname><given-names>NR</given-names></name> (<year>2001</year>) <article-title>Circulating tetrahydrobiopterin concentrations in patients with septic shock</article-title>. <source>Br J Anaesth</source>
<volume>86</volume>: <fpage>578</fpage>–<lpage>580</lpage>.
<?supplied-pmid 11573638?><pub-id pub-id-type="pmid">11573638</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Stroes</surname><given-names>E</given-names></name>, <name><surname>Kastelein</surname><given-names>J</given-names></name>, <name><surname>Cosentino</surname><given-names>F</given-names></name>, <name><surname>Erkelens</surname><given-names>W</given-names></name>, <name><surname>Wever</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>1997</year>) <article-title>Tetrahydrobiopterin restores endothelial function in hypercholesterolemia</article-title>. <source>J Clin Invest</source>
<volume>99</volume>: <fpage>41</fpage>–<lpage>46</lpage>.
<?supplied-pmid 9011574?><pub-id pub-id-type="pmid">9011574</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Heitzer</surname><given-names>T</given-names></name>, <name><surname>Brockhoff</surname><given-names>C</given-names></name>, <name><surname>Mayer</surname><given-names>B</given-names></name>, <name><surname>Warnholtz</surname><given-names>A</given-names></name>, <name><surname>Mollnau</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase</article-title>. <source>Circ Res</source>
<volume>86</volume>: <fpage>E36</fpage>–<lpage>41</lpage>.
<?supplied-pmid 10666424?><pub-id pub-id-type="pmid">10666424</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Cunnington</surname><given-names>C</given-names></name>, <name><surname>Van Assche</surname><given-names>T</given-names></name>, <name><surname>Shirodaria</surname><given-names>C</given-names></name>, <name><surname>Kylintireas</surname><given-names>I</given-names></name>, <name><surname>Lindsay</surname><given-names>AC</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease</article-title>. <source>Circulation</source>
<volume>125</volume>: <fpage>1356</fpage>–<lpage>1366</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.038919</pub-id>
<?supplied-pmid 22315282?><pub-id pub-id-type="pmid">22315282</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Longo</surname><given-names>N</given-names></name> (<year>2009</year>) <article-title>Disorders of biopterin metabolism</article-title>. <source>J Inherit Metab Dis</source>
<volume>32</volume>: <fpage>333</fpage>–<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-009-1067-2</pub-id>
<?supplied-pmid 19234759?><pub-id pub-id-type="pmid">19234759</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Zurfluh</surname><given-names>M</given-names></name>, <name><surname>Giovanni</surname><given-names>M</given-names></name>, <name><surname>Fiori</surname><given-names>L</given-names></name>, <name><surname>Gokdemir</surname><given-names>Y</given-names></name>, <name><surname>Baykal</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter paper</article-title>. <source>Mol Genet Metab</source>
<volume>86</volume>
<issue>Suppl 1</issue>: <fpage>S96</fpage>–<lpage>103</lpage>.
<?supplied-pmid 16275037?><pub-id pub-id-type="pmid">16275037</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Opladen</surname><given-names>T</given-names></name>, <name><surname>Abu Seda</surname><given-names>B</given-names></name>, <name><surname>Rassi</surname><given-names>A</given-names></name>, <name><surname>Thony</surname><given-names>B</given-names></name>, <name><surname>Hoffman</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Diagnosis of tetrahydrobiopterin deficiency using filter paper spots: further development of the method and 5 years experience</article-title>. <source>J Inherit Metab Dis</source>
<volume>34</volume>: <fpage>819</fpage>–<lpage>826</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-011-9300-1</pub-id>
<?supplied-pmid 21416196?><pub-id pub-id-type="pmid">21416196</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Ohashi</surname><given-names>A</given-names></name>, <name><surname>Suetake</surname><given-names>Y</given-names></name>, <name><surname>Saeki</surname><given-names>Y</given-names></name>, <name><surname>Harada</surname><given-names>T</given-names></name>, <name><surname>Aizawa</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Rapid clearance of supplemented tetrahydrobiopterin is driven by high-capacity transporters in the kidney</article-title>. <source>Mol Genet Metab</source>
<volume>105</volume>: <fpage>575</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2012.01.009</pub-id>
<?supplied-pmid 22318121?><pub-id pub-id-type="pmid">22318121</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref033">
                <label>33</label>
                <mixed-citation publication-type="book"><name><surname>Blau</surname><given-names>N</given-names></name>, <name><surname>Cotton</surname><given-names>R</given-names></name>, <name><surname>Hyland</surname><given-names>K</given-names></name> (<year>2001</year>) <chapter-title>Disorders of Tetrahydrobiopterin and Related Biogenic Amines</chapter-title> In: <name><surname>Scriver</surname><given-names>CR</given-names></name>, editor. <source>The Metabolic and Molecular Bases of Inherited Disease</source>. <edition>8th ed.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>
<?supplied-pmid 16006165?></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Karyana</surname><given-names>M</given-names></name>, <name><surname>Burdarm</surname><given-names>L</given-names></name>, <name><surname>Yeung</surname><given-names>S</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <name><surname>Wariker</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum</article-title>. <source>Malar J</source>
<volume>7</volume>: <fpage>148</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-7-148</pub-id>
<?supplied-pmid 18673572?><pub-id pub-id-type="pmid">18673572</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Tran</surname><given-names>TH</given-names></name>, <name><surname>Day</surname><given-names>NP</given-names></name>, <name><surname>Nguyen</surname><given-names>HP</given-names></name>, <name><surname>Nguyen</surname><given-names>TH</given-names></name>, <name><surname>Tran</surname><given-names>TH</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria</article-title>. <source>N Engl J Med</source>
<volume>335</volume>: <fpage>76</fpage>–<lpage>83</lpage>.
<?supplied-pmid 8649493?><pub-id pub-id-type="pmid">8649493</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Dondorp</surname><given-names>AM</given-names></name>, <name><surname>Desakorn</surname><given-names>V</given-names></name>, <name><surname>Pongtavornpinyo</surname><given-names>W</given-names></name>, <name><surname>Sahassananda</surname><given-names>D</given-names></name>, <name><surname>Silamut</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2</article-title>. <source>PLoS Med</source>
<volume>2</volume>: <fpage>e204</fpage>
<?supplied-pmid 16104831?><pub-id pub-id-type="pmid">16104831</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Yeo</surname><given-names>TW</given-names></name>, <name><surname>Lampah</surname><given-names>DA</given-names></name>, <name><surname>Gitawati</surname><given-names>R</given-names></name>, <name><surname>Tjitra</surname><given-names>E</given-names></name>, <name><surname>Kenangalem</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>105</volume>: <fpage>17097</fpage>–<lpage>17102</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0805782105</pub-id>
<?supplied-pmid 18957536?><pub-id pub-id-type="pmid">18957536</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Hyland</surname><given-names>K</given-names></name> (<year>1985</year>) <article-title>Estimation of tetrahydro, dihydro and fully oxidised pterins by hugh-performance liquid chromatography using sequential electrochemical and fluorometric detection</article-title>. <source>J Chromatogr</source>
<volume>343</volume>: <fpage>35</fpage>–<lpage>41</lpage>.
<?supplied-pmid 4066860?><pub-id pub-id-type="pmid">4066860</pub-id></mixed-citation>
              </ref>
              <ref id="ppat.1004667.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Hyland</surname><given-names>K</given-names></name>, <name><surname>Howells</surname><given-names>D</given-names></name> (<year>1988</year>) <article-title>Analysis and clinical significance of pterins</article-title>. <source>J Chromatogr</source>
<volume>429</volume>: <fpage>95</fpage>–<lpage>121</lpage>.
<?supplied-pmid 3062031?><pub-id pub-id-type="pmid">3062031</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
